Two breast cancer drugs get NHS approval
Two breast cancer drugs have been recommended for use by the NHS in England.
In draft guidance, the National Institute for Health and Care Excellence (NICE) has approved palbociclib (Ibrance) and ribociclib (Kisqali) for patients with advanced breast cancer.
The drugs are thought to slow the growth of the disease and delay the need for other treatments.
Cancer Research UK – who funded the Nobel Prize-winning researchers whose work underpinned the drugs' development – welcomed the announcement. Rose Gray, senior policy advisor at the charity, said:
"These decisions have taken some time, but we're pleased that the Government and NICE are taking steps to streamline the process so that patients can access life-saving drugs more quickly," she said.
To read the full article, click HERE
(Credit: Cancer Research UK)